Expression and modulation of progesterone induced blocking factor (PIBF) and innate immune factors in human leukemia cell lines by progesterone and mifepristone

References

• Check J H, Chase J S, Nowroozi K, Wu C H, Adelson H G. Progesterone therapy to decrease first trimester spontaneous abortions in previous aborters. Int J Fertil 1987; 32: 192–193, 197 – 199
   PubMedGoogle Scholar
• Check J H, Adelson H G. The efficacy of progesterone in achieving successful pregnancy. II. In women with pure luteal phase defects. Int J Fertil 1987; 32: 139–141
   PubMedGoogle Scholar
• Check J H, Nowroozi K, Wu C H, Adelson H G, Lauer C. Ovulation-inducing drugs versus progesterone therapy for infertility in patients with luteal phase defects. Int J Fertil 1988; 33: 252–256
   PubMedGoogle Scholar
• Formigli L, Roccio C, Belotti G, Stangalini A, Coglitore M T, Formigli G. Oocyte donation by gamete intrafallopian transfer to amenorrheic and cycling patients given replacement steroids. Hum Reprod 1989; 4: 772–776
   PubMed Web of Science ®Google Scholar
• Dubois C, Ulmann A, Baulieu E E. Contragestion with late luteal administration of RU486 (mifepristone). Fertil Steril 1988; 50: 593–596
   PubMed Web of Science ®Google Scholar
• Lahteenmaki P, Rapeli T, Kaariainen M, Alfthan H, Ylikorkala O. Late postcoital treatment against pregnancy with antiprogesterone RU486. Fertil Steril 1988; 50: 36–38
   PubMed Web of Science ®Google Scholar
• Bygdeman M, Swahn M L. Progesterone receptor blockage: effect on uterine contractility and early pregnancy. Contraception 1985; 32: 45–51
   PubMed Web of Science ®Google Scholar
• Bouman A, Heineman M J, Faas M M. Sex hormones and the immune response in humans. Hum Reprod Update 2005; 11: 411–423
   PubMed Web of Science ®Google Scholar
• Srivastava M, Anderson D JA. Progesterone receptor expression by human leukocyte cell lines: molecular mechanisms of cytokine suppression. Clin Exp Obst Gyn 2007; 34: 14–24
   PubMed Web of Science ®Google Scholar
• Szekeres-Bartho J, Kilar F, Falkay G, Csernus V, Torok A, Pacsa A S. The mechanism of the inhibitory effect of progesterone on lymphocyte cytotoxicity I. Progesterone treated lymphocytes release a substance inhibiting cytotoxicity and prostaglandin synthesis. Am J Reprod Immunol Microbiol 1985; 9: 15–18
   PubMed Web of Science ®Google Scholar
• Szekeres-Bartho J, Autran B, Debre P, Andreu G, Denver L, Chaouat G. Immunoregulatory effects of a suppressor factor from healthy pregnant women's lymphocytes after progesterone induction. Cell Immunol 1989; 122: 281–294
   PubMed Web of Science ®Google Scholar
• Szekeres-Bartho J, Faust Zs, Varga P. Progesterone-induced blocking factor (PIBF) in normal and pathological pregnancy. Am J Reprod Immunol 1995; 34: 342–348
   PubMed Web of Science ®Google Scholar
• Faust Z, Laskarin G, Rukavina D, Szekeres-Bartho J. Progesterone induced blocking factor inhibits degranulation of NK cells. Am J Reprod Immunol 1999; 42: 71–75
   PubMed Web of Science ®Google Scholar
• Szekeres-Bartho J, Reznikoff-Etievant M F, Varga P, Varga Z, Chaouat G. Lymphocyte progesterone receptors in human pregnancy. J Reprod Immunol 1989; 16: 239–247
   PubMed Web of Science ®Google Scholar
• Szekeres-Bartho J, Szekeres Gy, Debre P, Autran B, Chaouat G. Reactivity of lymphocytes to a progesterone receptor-specific monoclonal antibody. Cell Immunol 1990; 125: 273–283
   PubMed Web of Science ®Google Scholar
• Chiu L, Nishimure M, Ishii Y, Nieda M, Maeshima M, Takedani Y, et al. Enhancement of the expression of progesterone receptor on progesterone-treated lymphocytes after immunotherapy in unexplained spontaneous abortion. Am J Reprod Immunol 1996; 35: 552–557
   PubMed Web of Science ®Google Scholar
• Polgar B, Barakonyi A, Xynos I, Szekeres-Bartho J. The role of γ/δ T cell receptor positive cells in pregnancy. Am J Reprod Immunol 1999; 41: 239–244
   PubMed Web of Science ®Google Scholar
• Szekeres-Bartho J, Faust Z, Varga P, Szerday L, Kelemen K. The immunological pregnancy protective effects of progesterone is manifested via controlling cytokine production. Am J Reprod Immunol 1996; 35: 348–351
   PubMed Web of Science ®Google Scholar
• Szekeres-Bartho J, Par G, Dombay G, Smart C Y, Volgyi Z. The anti-abortive effect of PIBF in mice is manifested by modulating NK activity. Cell Immunol 1997; 177: 194–199
   PubMed Web of Science ®Google Scholar
• Makhseed M, Raghupathy R, Azizieh F, Omu A, Al-Shamali E, Ashkanani L. Th1 and Th2 cytokine profiles in recurrent aborters with successful pregnancy and with subsequent abortions. Hum Reprod 2001; 16: 2219–2226
   PubMed Web of Science ®Google Scholar
• Makhseed M, Raghupathy R, El-Shazly S, Azizieh F, Al-Harmi J A, Al-Azemi M M. Pro-inflammatory maternal cytokine profile in preterm delivery. Am J Reprod Immunol 2003; 49: 308–318
   PubMed Web of Science ®Google Scholar
• Szekeres-Bartho J, Faust Zs, Varga P. The expression of a progesterone-induced immunomodulatory protein in pregnancy lymphocytes. Am J Reprod Immunol 1995; 34: 342–348
   PubMed Web of Science ®Google Scholar
• Szekeres-Bartho J, Weill B J, Mike G, Houssin D, Chaouat G. Progesterone receptors in lymphocytes of liver-transplanted and transfused patients. Immunol Lett 1989; 22: 259–261
   PubMed Web of Science ®Google Scholar
• Check J H, Arwitz M, Gross J, Peymer M, Szekeres-Bartho J. Lymphocyte immunotherapy (LI) increases serum levels of progesterone induced blocking factor (PIBF). J Reprod Immunol 1997; 37: 17–20
   Web of Science ®Google Scholar
• Lachmann M, Gelbmann D, Kalman E, Polgar B, Buschle M, von Gabain A, et al. PIBF (progesterone induced blocking factor) is overexpressed in highly proliferating cells and associated with centrosome. Int J Cancer 2004; 112: 51–60
   PubMed Web of Science ®Google Scholar
• Szekeres-Bartho J, Autran B, Debre P, Andreu G, Denver L, Chaouat G. Immunoregulatory effects of a suppressor factor from healthy pregnant women's lymphocytes after progesterone induction. Cell immunol 1989; 122: 281–294
   PubMed Web of Science ®Google Scholar
• Srivastava M D, Srivastava B I. Expressionof mRNA and proteins for toll-like receptors, associated molecules, defensins, and LL-37 by SRIK-NKL, A CD8 + NK/T cell line. Leuk Res 2005; 29: 813–820
   PubMed Web of Science ®Google Scholar
• Kanai Y, Ushingima S, Dondo Y, Nakanishi Y, Hirshashi S. DNA methyltransferase expression and DNA methylation of stomach cancers. Int J Cancer 2001; 91: 205–212
   PubMed Web of Science ®Google Scholar
• Stroinigg N, Srivastava M D. Modulation of toll like receptor 7 and LL-37 expression in colon and breast epithelial cells by human beta-defeusm 2. Allergy Asthma Proc 2005; 26: 299–309
   PubMed Web of Science ®Google Scholar
• Polgar P, Kispal G, Lachmann M, Paar C, Nagy E, Csere P, et al. Molecular cloning and immunological characterization of a novel cDNA coding for PIBF. J Immunol 2003; 171: 5956–5963
   PubMed Web of Science ®Google Scholar
• Check J H, Ostrzenski A, Klimek R. Expression of an immunomodulatory protein known as progesterone induced blocking factor (PIBF) does not correlate with first trimester spontaneous abortions in progesterone supplemented women. Am J Reprod Immunol 1997; 37: 330–334
   PubMed Web of Science ®Google Scholar
• Check J H, Nazari P, Goldberg J, Yuan W, Angotti D. A model for potential tumor immunotherapy based on knowledge of immune mechanisms responsible for spontaneous abortion. Med Hypoth 2001; 57: 337–343
   PubMed Web of Science ®Google Scholar
• Kozma N, Halasz M, Polgar B, Poehlmann T G, Markert U R, Palkovics T, et al. Progesterone-induced blocking factor activates STAT 6 via binding to a novel IL-4 receptor. J Immunol 2006; 176: 819–826
   PubMed Web of Science ®Google Scholar
• Lee G W, Boomer J S, Gilman-Sachs A, Chedid A, Gudelj L, Rukavina D, et al. Regeneration and tolerance factor of the human placenta induces IL-10 production. Eur J Immunol 2001; 31: 687–691
   PubMed Web of Science ®Google Scholar
• Aslakson C J, Lee G, Boomer J S, Gilman-Sachs A, Kucuk O, Beaman K D. Expression of regeneration and tolerance factor on B cell chronic lymphocytic leukemias: a possible mechanism for escaping immune surveillance. Am J Hematol 1999; 61: 46–52
   PubMed Web of Science ®Google Scholar
• Naganuma H, Kono K, Mori Y, Takayoshi S, Stern P L, Tasaka K, et al. Oncofetal antigen 5T4 expression as a prognostic factor in patients with gastric cancer. Anticancer Res 2002; 22: 1033–1038
   PubMed Web of Science ®Google Scholar
• Kopreski M S, Benko F A, Gocke C D. Circulating RNA as a tumor marker: detection of 5T4 mRNA in breast and lung cancer patient serum. Ann N Y Acad Sci 2001; 945: 172–178
   PubMed Web of Science ®Google Scholar
• Kloosterboer H J, Deckers G H, Schoonen W GEJ. Pharmacology of two new very selective antiprogestagins: Org 31710 and Org 31806. Progesterone Antagonists in Reproductive Medicine and Oncology, H M Beier, I M Spitz. Oxford University Press, Oxford 1994; 47–52
   Google Scholar